Practically Speaking: The 411 on Keynote 811

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Elena Elimova takes us through the implementation of the Keynote 811 regimen in the management of Her2+ Gastro/GEJ cancer.  She focuses on the biomarkers, and treatment trajectory for patients in several different scenarios.  

Note: Biopsy after progression on 1st line Her2 targeted agents is recommended if 2nd line Her2 targeted agents are to be considered

Key Opinion Leader: 
Elena Elimova MD. MSc. FRCPC - elena.elimova@uhn.ca 
Assistant Professor Department of Medicine, Univeristy of Toronto 
Staff Medical Oncologist, Princess Margaret Hospital.

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Previous episodes: https://www.blogtalkradio.com/medoncnow